Latest News

Researchers at the University of Illinois at Chicago College of Medicine have discovered how the mutated huntingtin gene acts on the nervous system to create the devastation of Huntington’s disease. The report of their findings is available in Nature Neuroscience online. The researchers were able to show that the mutated...
HONG KONG, SHANGHAI and FLORHAM PARK, N.J. — HUTCHMED (China) Limited announced that the New Drug Application for sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (“ITP”) has been accepted for review and granted priority review by the China National Medical Products Administration (“NMPA”). Sovleplenib is a...
This is the second indication for Hiyasta® in Japan following adult T-cell leukemia/lymphoma (A TLL) SAN DIEGO – HUYABIO International, the leader in accelerating the global development of China’s pharmaceutical innovations, today announced the regulatory approval of HBI-8000, brand name Hiyasta®, monotherapy for the treatment of relapsed or refractory (R/R)...
HyVIS, the European project coordinated by the IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology), is about to start. By combining nanotechnology and optics, it will develop bionic synapses for retinal prostheses, designed to restore sight in people suffering from diseases such as retinitis pigmentosa and age-related macular degeneration (AMD)....
INDIANAPOLIS — Clinical research led by Indiana University School of Medicine investigators and their collaborators in Uganda has revealed that hydroxyurea significantly reduces infections in children with sickle cell anemia. Their latest findings enhance strong evidence of hydroxyurea’s effectiveness and could ultimately reduce death in children in Africa, the continent...
Hyper-cyclophosphamide, vincristine, doxorubicin, and dexamethasone plus rituximab (hyper-CVAD-R) can prevent central nervous system (CNS) relapse in patients with Burkitt leukemia/lymphoma (BL) or high-grade B-cell lymphoma (HGBL), according to a study published in Blood Advances. The retrospective study included 79 patients with newly diagnosed BL (n=54) or HGBL (n=25) who were treated...
SHANGHAI and GAITHERSBURG, Md. – I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in an abbreviated combination clinical study (NCT04202003) of lemzoparlimab (also known as TJC4) with azacitidine (AZA) in patients with newly...